Genting New Glory introduces a new drug for home use for PSVT, expanding its cardiovascular product lineup.

On March 23, Hong Kong-listed innovative pharmaceutical company Ascletis Pharma announced that it had reached an asset acquisition agreement with J-Star Pharmaceutical Hong Kong Limited. Ascletis Pharma will make an initial payment of 30 million US dollars plus up to a maximum of 20 million US dollars in development milestone payments to acquire the development, commercialization, and product rights of rimegepant nasal spray in the Greater China region.